IM Cannabis (IMCC) EBITDA (2020 - 2026)

IM Cannabis has reported EBITDA for 7 years, with the latest figure at -$1.5 million in Q2 2026.

• On a quarterly basis, EBITDA fell 498.15% year-over-year to -$1.5 million in Q2 2026; TTM through Jun 2026 was -$10.9 million, a 681.22% decrease from a year earlier, with the FY2025 full-year figure at -$8.3 million, down 10.95% from the prior year.
• EBITDA was -$1.5 million for Q2 2026 at IM Cannabis, down from -$1.2 million in the prior quarter.
• The five-year high for EBITDA was $7.0 million in Q1 2022, with the low at -$37.5 million in Q4 2022.
• Average EBITDA over 5 years is -$2.8 million, with a median of -$629197.0 recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: EBITDA soared 619.24% in 2022, then sank 1209.91% in 2026.
• Over 5 years, EBITDA stood at -$37.5 million in 2022, then jumped by 59.98% to -$15.0 million in 2023, then jumped by 96.27% to -$559794.0 in 2024, then sank by 827.69% to -$5.2 million in 2025, then jumped by 70.91% to -$1.5 million in 2026.
• The last three EBITDA figures came in at -$1.5 million (Q2 2026), -$1.2 million (Q1 2026), and -$5.2 million (Q4 2025), per Business Quant data.